"When it comes to safety, we don't need to establish harm."
– Daniel Gillen, during FDA's Cardiovascular and Renal Drug Advisory Committee's discussion on Cornerstone Therapeutics Inc.'s lixivaptan for hyponatremia

"Venture capital has placed too much money in the hands of too few people. I don't see most small biotechs ever getting venture funding unless it's strategic venture funding from pharmaceutical companies. It's really dried up for most of us."
– Judith Kelleher-Andersson, founder, president and chief scientific officer of NeuroNascent Inc., discussing the financing challenges confronting discovery- and development-stage biotechs

"The life science venture financing environment remains challenging. A potential bright spot is that we are seeing some increased involvement by large life science companies in the venture funding process. This makes sense, as large pharmaceutical and medical device companies need a healthy life science start-up industry to help fill their product pipelines."
– Barry Kramer, partner, Fenwick & West, commenting on the results of their First Half 2012 Life Science Venture Capital Survey